Search

EHA in EU-funded project on voluntary plasma collection capacity in Europe

EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)

Context: Plasma shortage 

Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Highlights from the SWG

Events
The ERIC International Preceptorship, Realizing Precision Medicine in CLL: Why and How
Stresa, Italy
November 17–18, 2023
PublicationsRecent ERIC publications include:

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia
Other malignancies in the history of CLL: an international multicenter study conducted…

Read more

Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation

EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1

 

Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the center of the EU policy and regulatory stage.

Read more

Rolling out CAR T across Europe

Prof Christine Chomienne talking about CAR T implementation challenges during the 7th EAPM Presidency Conference in Brussels.

Read more